AstraZeneca Pharma India Limited

Astazena’s $2 bn investment in Summit Therapeutics boosts its ADC oncology pipeline, aiming to bring advanced cancer treatments to market and enhance shareholder value.

Explore AstraZeneca Pharma India’s high‑growth outlook, strong oncology pipeline and analyst‑backed valuation for investors seeking pharma opportunities.

Goldman Sachs raises AstraZeneca target price to £163, citing strong drug pipeline, strategic partnerships, and resilient earnings—investors should watch upcoming earnings for confirmation.

Discover how AstraZeneca Pharma India balances lung‑cancer wins, Phase‑3 setbacks, and rare‑disease AI collaborations to stay ahead of rivals and market volatility.

Explore AstraZeneca Pharma India’s latest governance updates, annual report highlights, and market snapshot—insights for investors and pharma enthusiasts.

Discover how AstraZeneca Pharma India’s exclusive Zegfrovy license and new EGFR deal boost its oncology pipeline, unlock $600M upfront, and reshape cancer treatment in India.